NCT00907270

Brief Summary

Participants will be randomly assigned in one of two groups. Group A: oral supplementation with 4,000 IU of vitamin D (cholecalciferol). Group B: oral supplementation with 400 IU of vitamin D (cholecalciferol). Both treatments will be consumed daily for 6 months. Outcomes will be evaluated at baseline, three and six months. Variables related to leptin resistance will be evaluated. The main hypothesis is that vitamin D will diminish leptin resistance in overweight and obese women. If the hypothesis is confirmed, women will show a reduction in the Resting energy expenditure: serum Leptin ratio (REE: Leptin ratio), as well as a reduction of hunger, body weight, body and abdominal fat and an increase in resting energy expenditure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2009

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 22, 2009

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2009

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

May 22, 2009

Status Verified

May 1, 2009

Enrollment Period

8 months

First QC Date

May 20, 2009

Last Update Submit

May 20, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluation of leptin resistance: (resting energy expenditure: leptin ratio) before and after (3 and 6 months) supplementation with vitamin D3 (cholecalciferol) 4,000 or 400 IU/day.

    basal, third and sixth month

Secondary Outcomes (1)

  • Effect of vitamin D supplementation (25-OH-D): hunger, body weight, energy intake, resting energy expenditure, and body fat, improvement on low intensity chronic inflammation, SOCS-3 expression and JAK2/STAT3 signal.

    Basal, third and sixth month

Study Arms (2)

Cholecalciferol: 400 IU/day

ACTIVE COMPARATOR

Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)

Dietary Supplement: Cholecalciferol

Cholecalciferol 4000 IU/day

EXPERIMENTAL

Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D

Dietary Supplement: Cholecalciferol

Interventions

CholecalciferolDIETARY_SUPPLEMENT

Cholecalciferol: 4,000 IU/day and 400 IU/day

Also known as: Cholecalciferol supplementation (400 IU and 4000 IU)
Cholecalciferol 4000 IU/dayCholecalciferol: 400 IU/day

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI: 25-29.9
  • Serum vitamin D levels: 20-80 nmol/L (25-OH-D)

You may not qualify if:

  • Liver disease
  • Kidney disease
  • Diabetes mellitus
  • Malignity
  • Any kind of hormonal disorder
  • Medication that modify hunger/satiety answer and those medications that alter -the glucose/insulin metabolism
  • Subjects with diet treatment to lose weight

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Social Insurance

Cuernavaca, Morelos, 62450, Mexico

Location

MeSH Terms

Conditions

OverweightObesity

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Mario Flores-Aldana, MsC

    National Institute of public Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mario Flores-Aldana, MsC

CONTACT

Nayeli Macías-Morales, MsC

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

May 20, 2009

First Posted

May 22, 2009

Study Start

September 1, 2009

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

May 22, 2009

Record last verified: 2009-05

Locations